Mechanisms of Cancer and Treatment-related Symptoms and Toxicities (R21) | Apply Online

Frequently Asked Questions (FAQs)

What is the focus of the "Mechanisms of Cancer and Treatment-related Symptoms and Toxicities (R21)" opportunity (PA 16-258)?

This NIH funding opportunity supports early-stage, exploratory research aimed at understanding why cancer- and treatment-related symptoms and toxicities occur, and why those experiences can differ widely between patients. It is centered on mechanistic research that looks beyond biology alone and examines how biological processes interact with cognitive, behavioral, and sociocultural influences across the cancer care trajectory.

Which agency sponsors this funding opportunity?

The sponsor is the National Institutes of Health (NIH), within the U.S. Department of Health and Human Services. The agency listing provided is HHS-NIH11.

What does the R21 mechanism mean in practical terms for applicants?

The R21 mechanism is intended for innovative pilot projects and feasibility studies. In practical terms, this opportunity is meant to fund smaller, hypothesis-generating or proof-of-concept research rather than large, definitive trials. The expectation is that R21-funded work will generate preliminary data that positions the research team for a larger next step, such as a cohort study or a mechanistically driven intervention project that could later fit an NIH R01.

What kinds of research projects are considered a good fit for this FOA?

Projects are a strong fit when they aim to clarify mechanisms, identify measurable contributors to symptoms/toxicities, test whether a new model or method is workable, and produce evidence sufficient to justify a larger and more conclusive study. The FOA encourages research that examines complex interactions across biological, cognitive/behavioral, and sociocultural domains.

What symptoms and toxicities does the FOA highlight?

Examples described include pain, fatigue, cognitive changes, nausea, sleep problems, neuropathy, mood disturbance, and other treatment toxicities. The FOA is broadly concerned with both symptoms and toxicities related to cancer and its treatment.

Does the FOA address both short-term and long-term problems?

Yes. A central priority is improving understanding of factors associated with both acute and chronic symptoms and toxicities. Acute issues can include immediate treatment side effects and short-term symptom flares, while chronic issues can include long-lasting or late-emerging problems such as persistent fatigue, chronic pain, long-term cardiotoxicity, cognitive impairment, sexual dysfunction, or ongoing psychological distress.

What does the FOA mean by studying "mechanisms" of symptoms and toxicities?

Mechanistic work, as described here, focuses on identifying and explaining the underlying pathways and contributing factors that lead to symptom onset, severity, persistence, or response to intervention. The FOA emphasizes measurable pathways and relationships that can tie symptom experiences to underlying contributors.

Is there an emphasis on measurement and quantification?

Yes. The FOA emphasizes identifying, describing, and quantifying contributing factors, whether those factors act independently or in combination. The focus on quantification indicates interest in measurable relationships such as biomarkers and signaling pathways, genetic or epigenetic contributors, treatment exposures, comorbidities, patient-reported outcomes, and objective functional measures.

What biological factors are within the scope of this FOA?

The FOA explicitly encourages biological factors such as inflammatory pathways, immune dysregulation, neurotoxicity, metabolic or hormonal shifts, organ damage, microbiome changes, pharmacogenomics, and tumor-related processes.

What cognitive and behavioral factors are within the scope of this FOA?

Examples include symptom appraisal, coping, expectations, adherence, activity levels, sleep behaviors, nutrition, substance use, and self-management strategies.

What sociocultural factors are within the scope of this FOA?

Examples include social support, caregiving context, socioeconomic conditions, health literacy, language access, discrimination and stress exposures, cultural beliefs about illness and treatment, and barriers to symptom reporting or obtaining care.

Is the FOA specifically interested in multi-domain or biopsychosocial models?

Yes. The FOA highlights that symptoms and toxicities are shaped by a dynamic mix of biological mechanisms and cognitive, behavioral, and sociocultural influences that interact across the cancer care trajectory. Proposals that align with multilevel or biopsychosocial models, and that test how these factors jointly influence outcomes, are consistent with the stated emphasis on complex interaction.

How does this FOA connect to future NIH funding or larger studies?

The FOA positions the R21 as a catalyst. It expects that results from these exploratory projects will lay the groundwork for larger cohort studies to validate findings or for the development and testing of novel, mechanistically driven interventions that could later be pursued through an NIH R01.

Is the opportunity intended to support large clinical trials?

No. Based on the description provided, it is intended for smaller, exploratory pilot projects and feasibility studies rather than large definitive trials.

Does the FOA encourage work focused on underserved or underrepresented populations?

Yes. The FOA places special emphasis on generating new insights for populations often underrepresented in symptom and toxicity research, including minority and underserved groups, older adults, and pediatric, adolescent, and young adult patients.

What is the intent behind emphasizing underrepresented populations?

The intent is not only to include these groups, but to better understand how mechanisms and contributing factors may differ due to developmental stage, comorbidities, treatment patterns, access to care, structural inequities, or culturally shaped experiences of symptoms and communication with clinicians. Studies designed to address disparities in symptom burden, toxicity risk, or symptom management outcomes align with this priority.

What types of organizations are eligible to apply?

Eligibility is broad and includes: state, county, and local governments; public and state-controlled and private institutions of higher education; independent school districts; special district governments; federally recognized tribes and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and other eligible entities as described in the full announcement.

Is this opportunity limited to academic institutions?

No. The eligibility list includes many organization types beyond universities, including governments, tribal entities, nonprofits (with or without 501(c)(3)), and for-profit organizations (including small businesses, and for-profits other than small businesses).

What is the maximum award amount (award ceiling) for this opportunity?

The award ceiling listed is $200,000, consistent with the smaller, exploratory nature of the R21 mechanism.

What is the CFDA number associated with this program?

The CFDA number provided is 93.393.

What are the posted and closing dates listed in the source information?

The opportunity was created and posted on May 16, 2016. The closing date listed in the source data is September 7, 2019.

What cancer care time periods are included in the research scope?

The FOA frames symptom and toxicity experiences across the entire cancer care trajectory, from diagnosis and active treatment through survivorship or end-of-life care.

What kinds of outcomes or measures might be relevant based on the FOA description?

Based on the description, relevant measures can include biomarkers and other biological indicators, treatment exposure variables, comorbidity information, patient-reported outcomes, and objective functional measures, particularly when they help link symptom burden to underlying mechanisms.